Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
GlobeNewswire
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and..